

Pharmacotherapy Management of COPD Exacerbation (PCE)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS[®]) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for pharmacotherapy management of COPD exacerbation.

What is the measure?

This measure focuses on COPD exacerbations for members age 40 and older who had an acute inpatient discharge or emergency department visit on or between January 1 and November 30 of the measurement year and who were dispensed appropriate medications.

Two rates are reported:

1. Dispensed a systemic corticosteroid (or there was evidence of an active prescription) within 14 days of the event
2. Dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event

How To Improve Your Quality Score

- Schedule a follow-up appointment post discharge and ensure your patient has the appropriate medications.
- Ask if your patient has a barrier to filling the prescription. Many drug manufacturers have coupons available on their websites.

Systemic Corticosteroids

The member is compliant if they are dispensed a prescription for systemic corticosteroids that are active on the relevant date (on or 14 days after the episode).

Description

Glucocorticoids

Prescription

Cortisone, Dexamethasone, Hydrocortisone, Methylprednisolone, Prednisolone, Prednisone

(Continued next page)

HEDIS Measure: Pharmacotherapy Management of COPD Exacerbation (PCE) *(continued)*

Bronchodilators

The member is compliant if they are dispensed a prescription for systemic corticosteroids that are active on the relevant date (on or 30 days after the episode date).

Description

Anticholinergic agents

Prescription

Acclidinium-bromide, Ipratropium, Tiotropium, Umeclidinium

Beta 2-agonists

Albuterol, Arformoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Salmeterol

Bronchodilator combinations

Albuterol ipratropium, Budesonide-formoterol, Fluticasone-salmeterol, Fluticasone-vilanterol, Fluticasone furoate-umeclidinium-vilanterol, Formoterol-acclidinium, Formoterol-glycopyrrolate, Formoterol-mometasone, Glycopyrrolate-indacaterol, Olodaterol-tiotropium, Umeclidinium-vilanterol

Exclusions

- Members in hospice or receiving hospice services during the measurement year
- Members who died during the measurement year

Diagnosis Codes

Chronic Bronchitis	ICD10: J41.0 -- J41.1, J41.8, J42
COPD	ICD10: J44.0 – J44.1, J44.9
Emphysema	ICD10: J43.0 – J43.2, J43.8 – J43.9

Exclusion Codes

Hospice encounter	HCPCS: G9473 – G9479, G5003-5008, G5010, S9126, T2042 – T2046
Hospice intervention	CPT: 99377 – 99378, HCPCS: G0182

Content reproduced with permission from HEDIS® MY 2023, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit ncqa.org/publications